The vascular side of COVID-19 disease. Position paper of the International Union of Angiology
| Autor: | Yongquan Gu, Armando Mansilha, Giacomo Failla, L. Aluigi, Luca Costanzo, Jan Pitha, Thomas Karplus, Jawied Fareed, Pier Luigi Antignani |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Consensus medicine.drug_class Cardiology Low molecular weight heparin Disease 030204 cardiovascular system & hematology 030230 surgery Bioinformatics 03 medical and health sciences 0302 clinical medicine medicine Coagulopathy Humans Pandemics Societies Medical Endotheliitis Angiology SARS-CoV-2 business.industry Pyroptosis Anticoagulants COVID-19 Thrombosis medicine.disease COVID-19 Drug Treatment Pulmonary embolism Cardiology and Cardiovascular Medicine business |
| Zdroj: | International Angiology. 39 |
| ISSN: | 1827-1839 0392-9590 |
| DOI: | 10.23736/s0392-9590.20.04539-3 |
| Popis: | The SARS-CoV-2 infection (COVID-19) is causing an ongoing pandemic and potentially fatal disease. Development of coagulopathy with thrombotic complications such as deep vein thrombosis and pulmonary embolism are emerging as factors for progression to severe disease and death. Also, a markedly increased level of D-dimer, a protein product of fibrin degradation, has been associated to mortality. Furthermore, activation of immune response due to virus infection may led to uncontrolled severe inflammation with damage to host cells and induction of endotheliitis and cellular apoptosis and pyroptosis. The use of low molecular weight heparin in early stage of the disease could prevent vascular complications and reduce the progression to severe stage of the disease. Aim of this paper was to summarize current evidence about vascular involvement in COVID-19 disease and potential antithrombotic therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|